Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) on Course for Private Demonstrations of the i/Blue Imaging System(TM) at the American Urological Association Annual Conference in September
Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDABladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and managementImagin Medical plans to complete its proprietary i/Blue…